CMND · Clearmind Medicine Inc.

Clearmind Medicine Inc. is proactively positioning its lead candidate, CMND-100 (MEAI), for potential FDA Breakthrough Therapy Designation (BTD) following encouraging results from its ongoing Phase I/IIa clinical trial for Alcohol Use Disorder. The announcement highlights the company's strategy to leverage recent regulatory tailwinds, specifically an Executive Order signed by President Trump aimed at accelerating FDA review processes for certain psychedelic and neuroplastogen therapies. While the company believes the preliminary clinical evidence may meet the rigorous criteria for BTD—intended for drugs treating serious conditions with potential substantial improvement over existing therapies—management clarified that no formal request has been submitted to the FDA as of the filing date. The candidate is characterized as a non-hallucinogenic, second-generation neuroplastogen-derived therapeutic, addressing a significant unmet medical need in a life-threatening condition affecting millions globally.